ORCA
Online Research @ Cardiff

Browse by Current Cardiff authors

Number of items: 20.

de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A and Lassen, Ulrik 2019. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncology 20 (3) , pp. 383-393. 10.1016/S1470-2045(18)30859-3

Peltola, Katriina J., Bono, Petri, Jones, Robert Hugh, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen, Mika V.J., Fizazi, Karim and Massard, Christopher 2019. ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer. European Urology Focus 10.1016/j.euf.2018.08.022
Item availability restricted.

Basu, B, Krebs, M G, Sundar, R, Wilson, R H, Spicer, J, Jones, R, Brada, M, Talbot, D C, Steele, N, Ingles Garces, A H, Brugger, W, Harrington, E A, Evans, J, Hall, E, Tovey, H, de Oliveira, F M, Carreira, S, Swales, K, Ruddle, R, Raynaud, F I, Purchase, B, Dawes, J C, Parmar, M, Turner, A J, Tunariu, N, Banerjee, S, de Bono, J S and Banerji, U 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29 (9) , pp. 1918-1925. 10.1093/annonc/mdy245

Clarke, Noel, Wiechno, Pawel, Alekseev, Boris, Sala, Nuria, Jones, Robert, Kocak, Ivo, Chiuri, Vincenzo Emanuele, Jassem, Jacek, Fléchon, Aude, Redfern, Charles, Goessl, Carsten, Burgents, Joseph, Kozarski, Robert, Hodgson, Darren, Learoyd, Maria and Saad, Fred 2018. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology 19 (7) , pp. 975-986. 10.1016/S1470-2045(18)30365-6

Scurr, Martin J, Pembroke, Tom, Bloom, Anja, Roberts, David J, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard A, Brewster, Alison E, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Hills, Robert, Gallimore, Awen and Godkin, Andrew 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research , clincanres.0895.2017. 10.1158/1078-0432.CCR-17-0895

Reza, Mariana, Jones, Robert, Aspegren, John, Massard, Christophe, Mattila, Leena, Mustonen, Mika, Wollmer, Per, Trägårdh, Elin, Bondesson, Eva, Edenbrandt, Lars, Fizazi, Karim and Bjartell, Anders 2016. Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study. European Urology Focus 2 (5) , pp. 547-552. 10.1016/j.euf.2016.01.005

Fizazi, Karim, Massard, Christophe, Bono, Petri, Jones, Robert, Kataja, Vesa, James, Nicholas, Garcia, Jorge A, Protheroe, Andrew, Tammela, Teuvo L, Elliott, Tony, Mattila, Leena, Aspegren, John, Vuorela, Annamari, Langmuir, Peter and Mustonen, Mika 2014. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology 15 (9) , pp. 975-985. 10.1016/S1470-2045(14)70240-2

Greenow, Kirsty Rhian, Clarke, Alan Richard, Williams, Geraint Trefor and Jones, Robert H. 2013. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33 , pp. 4089-4096. 10.1038/onc.2013.371

Greenow, Kirsty Rhian, Clarke, Alan Richard and Jones, Robert H. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28 (11) , pp. 1443-1453. 10.1038/onc.2008.482

Robinson, H. M. R., Jones, Robert H., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25 (39) , pp. 5359-5369. 10.1038/sj.onc.1209532

Jones, Robert H., Reubi, Jean-Claude, Millan, David and Vasey, Paul 2004. Octreotide: an active agent in epithelial ovarian carcinoma? The Lancet Oncology 5 (4) , pp. 251-253. 10.1016/S1470-2045(04)01430-5

Jones, Robert H., Goldstein, David, Kurtovic, Jelica, Keogh, Gregory and Riordan, Stephen M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98 (5) , pp. 1211-1213. 10.1016/S0002-9270(03)00170-9

Jones, Robert H., Ryan, Mary and Friedlander, Michael 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89 (1) , pp. 112-115. 10.1016/S0090-8258(03)00066-0

Jones, Robert H. and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39 (2) , pp. 147-156. 10.1016/S0959-8049(02)00612-3

Jones, Robert H. and Vasey, Paul A 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4 (12) , pp. 738-747. 10.1016/S1470-2045(03)01279-8

Twelves, Chris and Jones, Robert H. 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy 2 (9) , pp. 1495-1505. 10.1517/14656566.2.9.1495

Millar, J. B., McGowan, C. H., Lenaers, G., Jones, Robert and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10 (13) , pp. 5610-5621.

Jones, Robert and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86 (7) , pp. 2176-2180.

Jones, Robert, Moreno, Sergio, Nurse, Paul and Jones, Nicholas C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53 (4) , pp. 659-667. 10.1016/0092-8674(88)90581-8

This list was generated on Fri Aug 23 05:14:56 2019 BST.

Export as	Atom RSS 1.0 RSS 2.0